Clinical Trial Update: Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of Cervarix (HPV vaccine) in HIV-infected females has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer Prevention
• Human Papillomavirus Infection
• Papillomavirus Infections

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 2 | Status: COMPLETED | Results posted: 2012-03-22